Published 1st June 2016

Inivata's InVision ctDNA assay presented at ASCO Annual meeting 2016

Imperial Innovations notes its portfolio company, Inivata, a clinical cancer genomics business, will introduce its proprietary InVision™ ctDNA assay for broad molecular profiling during the 2016 annual meeting of the American Society of Clinical Oncology (ASCO) at McCormick Place in Chicago, Illinois, June 3-7 2016.

The InVision™ assay utilizes the innovative application of Inivata’s proprietary enhanced tagged-amplicon sequencing (eTAm-Seq™) platform for genomic analysis, which was developed by Inivata on the basis of the TAm-Seq™ technology from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge. InVision™ was developed to serve as a reliable, multi-gene, support tool for oncologists to accurately translate genomic alterations into actionable information to inform clinical decision making and improve cancer treatment planning for the patient. Commercial availability of the InVision™ assay will be the subject of a future announcement.

Read more at the company's website